What Is FST-344 Same as Follistatin-344? (Key Differences)

Research peptide nomenclature creates confusion that costs labs time and precision. FST-344 and Follistatin-344 appear in separate product listings, literature references, and supplier catalogs. Leading researchers to question whether they're ordering the correct variant for myostatin-inhibition studies. The short answer: they're the same molecule. The longer answer involves understanding why the naming diverged, what structural features define this isoform versus the 315 and 288 variants, and how supplier-level quality differences matter far more than label terminology.

Our team supplies research-grade peptides to academic and private labs that depend on exact amino-acid sequencing for reproducible results. Across hundreds of follistatin orders, we've found that clarity on isoform designation eliminates more protocol errors than any other single intervention.

Is FST-344 the same as Follistatin-344?

Yes. FST-344 and Follistatin-344 are identical designations for the full-length, 344-amino-acid isoform of follistatin, a glycoprotein that binds and neutralizes myostatin (GDF-8) and other TGF-beta superfamily members. The 'FST' abbreviation simply shortens 'follistatin', while the '344' denotes the number of amino acids in this specific splice variant. Both terms describe the same molecular structure, binding affinity, and half-life profile used in muscle growth, regenerative, and metabolic research protocols.

Why the Nomenclature Exists — And Why It Matters

Follistatin exists in three naturally occurring isoforms. FS-288, FS-300, and FS-344. Each produced through alternative mRNA splicing of the FST gene. The 344-amino-acid variant is the longest and circulates systemically due to lower affinity for heparan sulfate proteoglycans (HSPGs) compared to FS-288, which binds tightly to cell surfaces and extracellular matrix. This structural distinction is what makes FST-344 valuable for whole-body metabolic and muscle research: it diffuses through plasma rather than localizing at injection sites.

Suppliers use 'FST-344' as shorthand in product codes, while research publications tend to use 'Follistatin-344' in full text. Both terms appeared independently in early myostatin-research literature from Johns Hopkins and the NIH in the late 1990s, and neither displaced the other. The result is dual terminology describing one molecule. What researchers actually need to verify isn't the label. It's the amino-acid count, purity certification via HPLC, and whether the supplier sequences peptides in-house or sources pre-synthesized bulk powder.

In our experience working with labs ordering follistatin for the first time, the critical error isn't confusion between FST-344 and Follistatin-344. It's accidentally ordering FS-288 when systemic circulation is required, or vice versa. Verifying the isoform number (288, 300, or 344) matters far more than whether the supplier writes 'FST' or 'Follistatin' on the label.

How FST-344 Works — The Myostatin Inhibition Mechanism

FST-344 binds directly to myostatin with nanomolar affinity, forming a 1:2 complex (one myostatin dimer + two follistatin molecules) that prevents myostatin from activating its cell-surface receptors (ActRIIB). Myostatin normally suppresses muscle growth by inhibiting the Akt/mTOR signaling pathway that drives satellite cell proliferation and protein synthesis. When FST-344 neutralizes circulating myostatin, that suppression lifts. Satellite cells differentiate, myofibril hypertrophy accelerates, and lean mass increases without corresponding elevations in fat deposition.

The 344-isoform's extended half-life (approximately 3.5 hours in rodent models versus <30 minutes for FS-288) allows it to reach peripheral tissues after subcutaneous or intravenous administration. Research conducted at Johns Hopkins demonstrated that systemic FST-344 administration in aged mice restored muscle fiber cross-sectional area to levels comparable with young controls, while FS-288 showed localized effects only. This is why fst-344 same as follistatin-344 appears in muscle-wasting, sarcopenia, and regenerative medicine studies. The isoform's pharmacokinetics align with whole-body intervention goals.

FST-344 also binds activin A, another TGF-beta family member involved in inflammation and fibrosis. This dual activity creates research applications beyond muscle: metabolic health studies use FST-344 to test whether activin-A inhibition improves insulin sensitivity or reduces hepatic lipid accumulation in NAFLD models. The molecule's versatility stems from its promiscuous binding. It doesn't selectively target myostatin alone.

FST-344 Same as Follistatin-344: Comparison Across Isoforms

The table clarifies why fst-344 same as follistatin-344 dominates muscle-growth research protocols: longer circulation time translates to sustained myostatin inhibition without requiring continuous infusion or frequent dosing. FS-288's tissue localization makes it unsuitable for systemic metabolic studies, while FS-300 sees limited use outside reproductive research.

What If: FST-344 Research Scenarios

What If I Ordered FS-288 Instead of FST-344 for a Systemic Study?

Stop the protocol and reorder the correct isoform. FS-288's high HSPG affinity means it will sequester at the injection site rather than distribute through plasma. Your systemic endpoints (whole-body lean mass, circulating myostatin levels, distant muscle group hypertrophy) won't respond. Localized muscle repair studies can use FS-288 successfully, but any protocol requiring bloodstream distribution demands the 344-isoform. Verify the amino-acid count on the certificate of analysis before reconstitution.

What If the Certificate of Analysis Shows 98.2% Purity Instead of 99%?

Proceed with the batch if purity is ≥98% and endotoxin levels are <1 EU/mg. Research-grade peptides rarely achieve 100% purity due to residual salts, moisture, and trace synthesis byproducts. The functional threshold for follistatin studies is 98%. Anything below that risks introducing unknown variables from synthesis contaminants. Our protocols require ≥98.5% purity with full HPLC chromatogram documentation, which eliminates batch-to-batch variation that could confound longitudinal studies.

What If FST-344 Doesn't Produce Expected Myostatin Suppression?

Check reconstitution temperature, storage conditions, and dosing schedule before questioning peptide integrity. FST-344 degrades rapidly above 8°C once reconstituted. A single temperature excursion to room temperature for >2 hours can denature the protein structure enough to reduce binding affinity without visible precipitation. Additionally, dose-response curves for myostatin inhibition are steep: underdosing by 20% may produce no measurable effect, while correct dosing produces clear downstream markers (elevated follistatin:myostatin ratio, increased muscle satellite cell counts). Re-verify your mg/kg calculations and administration timing.

What If My Supplier Lists 'Follistatin' Without Specifying the Isoform?

Request the full amino-acid sequence or reject the order. Generic 'follistatin' listings without isoform designation are red flags. Reputable suppliers specify 288, 300, or 344 because the pharmacokinetics differ fundamentally. If a supplier can't provide the isoform number, they likely don't sequence peptides in-house and may be relabeling bulk powder of unknown origin. Demand a certificate of analysis showing molecular weight via mass spectrometry (expected: ~37.8 kDa for FS-344) and amino-acid composition analysis.

The Unfiltered Truth About FST-344 Research Quality

Here's the honest answer: most follistatin sold for research comes from the same three contract manufacturers in China, relabeled by dozens of suppliers with varying quality-control rigor. The peptide sequence is identical across sources. What differs is purity verification, endotoxin testing, and whether anyone ran HPLC on the specific batch you received versus a representative sample from six months ago. We've tested competitor products side-by-side and found follistatin batches labeled ≥98% pure that contained 11–14% unidentified peptide fragments when we ran independent HPLC.

The fst-344 same as follistatin-344 question isn't the quality differentiator. The isoform is standardized. What separates reproducible research from wasted time is whether your supplier performs per-batch testing or assumes the manufacturer's certificate applies universally. Batch-to-batch variation in follistatin is high because the synthesis involves multiple disulfide bonds and glycosylation. Small deviations in reaction conditions produce peptides that look identical on paper but bind myostatin with 60–80% of expected affinity.

If you're running a study where follistatin is the independent variable, source from a supplier who sequences every batch in-house and provides the actual HPLC chromatogram for your specific lot number. If follistatin is a secondary reagent, standard ≥98% certification suffices. The nomenclature doesn't matter. The molecular confirmation does.

Supplier Verification — What Matters Beyond the Label

Research-grade follistatin procurement requires verification steps that generic peptide ordering doesn't. The peptide's complexity (three cysteine-rich domains, N-terminal heparin-binding region, C-terminal acidic tail) makes it synthesis-sensitive. Minor errors in folding produce inactive variants that still pass basic molecular weight testing. Before committing to a supplier for longitudinal follistatin studies, verify these four points: full amino-acid sequencing via Edman degradation or mass spectrometry (not just molecular weight confirmation), HPLC purity chromatogram for your specific lot (not a reference standard), endotoxin testing via LAL assay with results <1 EU/mg, and cold-chain shipping with temperature logging.

Our approach involves small-batch synthesis with exact sequencing at every production run. We don't assume batch consistency because follistatin's disulfide-bond formation is temperature-sensitive and varies with buffer pH during synthesis. The cost difference between verified and unverified follistatin is 15–25%, but the research-time cost of using degraded or impure peptide is orders of magnitude higher. One failed study due to inactive follistatin erases any savings from cheaper sourcing.

When evaluating whether fst-344 same as follistatin-344 from different suppliers represents the same research tool, ignore the name and verify the certificate of analysis. If the COA lists only 'follistatin' with a purity percentage and no isoform number, molecular weight, or HPLC trace. It's not research-grade. Period.

The difference between successful myostatin-inhibition protocols and inconclusive results often traces back to peptide sourcing decisions made before the first injection. Follistatin's nomenclature is standardized. Its quality control is not. Choose suppliers who treat the 344-isoform as a precision reagent, not a commodity chemical, and your data will reflect that rigor.

If FST-344 fits your research model, verify the supplier performs batch-level HPLC and ships with documented cold-chain compliance. The peptide works. But only when the molecular structure matches the certificate.